{"id":25202,"date":"2026-06-12T12:50:36","date_gmt":"2026-06-12T10:50:36","guid":{"rendered":"https:\/\/www.fbg.ub.edu\/?page_id=25202"},"modified":"2026-06-12T12:50:36","modified_gmt":"2026-06-12T10:50:36","slug":"vacv-atf6n-the-tumour-killer-virus","status":"publish","type":"page","link":"https:\/\/www.fbg.ub.edu\/en\/what-we-do\/technologies-materials-and-licences\/technologies-for-licencing\/vacv-atf6n-the-tumour-killer-virus\/","title":{"rendered":"VACV-ATF6(N): The tumour-killer virus"},"content":{"rendered":"<h3>Executive summary<\/h3>\n<p>A research group, with wide experience on immunno-oncology, has engineered a virus that selectively replicates in cancer cells while actively stimulating anti-tumour immunity.<\/p>\n<h3>Introduction<\/h3>\n<p>Solid tumors account for ~90% of all cancer patients, being ~17M new diagnoses each year worldwide. The efficacy of immunotherapies is limited by tumor-driven immune evasion mechanisms.<\/p>\n<p>Colorectal Carcinoma (CRC) is the third most common cancer globally. As of 2026, the global CRC therapeutics market is valued at $14.25 billion. This market is driven by rising incidence rates and a significant shift toward immunotherapy, which is projected to grow at a 14.21% CAGR through 2031.<\/p>\n<p>While CRC is our lead indication, our oncolytic platform is designed for expansion into other high-growth solid tumor markets such as pancreatic cancer and RRC.<\/p>\n<h3>Description<\/h3>\n<p>Engineered vaccinia virus (VACV) expressing ATF6(N) to hyperactivate the unfolded protein response (UPR) in infected cells, promoting immunogenic cell death (ICD).<\/p>\n<p>ICD enhances tumor antigen release and presentation, triggering potent adaptative antitumor immune response.<\/p>\n<p><em>Thymidine kinase (TK) deletion restricts viral replication to tumor cells.<\/em><\/p>\n<h3><strong>Current stage of development<\/strong><\/h3>\n<p>There is an ongoing development plan to perform the in vivo proof of concept.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Executive summary A research group, with wide experience on immunno-oncology, has engineered a virus that selectively replicates in cancer cells&#8230;<\/p>\n","protected":false},"author":2,"featured_media":25200,"parent":1398,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-tecnologies.php","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"class_list":["post-25202","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/25202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=25202"}],"version-history":[{"count":1,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/25202\/revisions"}],"predecessor-version":[{"id":25204,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/25202\/revisions\/25204"}],"up":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/pages\/1398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media\/25200"}],"wp:attachment":[{"href":"https:\/\/www.fbg.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=25202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}